The patent on the tuberculosis drug bedaquiline expires today (July 18). But while its manufacturer, Johnson & Johnson, intends to use secondary patents to extend its exclusive right to sell the drug, an innovative deal will lower its price and expand access to millions around the globe. The drug improves the outcomes for patients with multidrug-resistant tuberculosis, reducing the risk of death by approximately 10%, according to a study in BMC Infectious Diseases, a U.K.